Table 3.
Sensitive analyses according to the presence or absence of Hypertension in the MANGUE cohort.
| |
No hypertension | Hypertension | |
|---|---|---|---|
| N=10 | N=48 | ||
| Univariate analyses | p value | ||
| General characteristics | |||
| Age, years | 37 (23-41) | 49 (39-66) | 0.003 |
| Gender M/F, N (%) | 3/7 (30.0/70.0) | 32/16 (66.7/33.3) | 0.04 |
| BMI, kg/m² | 24.3 [20.7-27.2] | 23.4 [22.4-28.6] | 0.48 |
| First transplantation, N (%) |
8 (80.0) | 41 (85.4) | 0.65 |
| Living donors, N (%) | 1 (10.0) | 5 (10.4) | 1 |
| Delayed Graft function, N (%) |
1 (10.0) | 5 (10.4) | 1 |
| Expanded criteria donors, N (%) |
2 (20.0) | 20 (42.6) | 0.29 |
| Cardiovascular disease, N (%) |
0 | 10 (20.8) | 0.18 |
| Hypertension before transplantation, N (%) |
6 (60.0) | 38 (79.2) | 0.23 |
| Diabetes (including NODAT), N (%) |
4 (40.0) | 10 (20.8) | 0.2 |
| Graft rejection before inclusion, N (%) |
1 (10.0) | 1 (2.1) | 0.32 |
| eGFR, ml/min/ 1,73m2 |
47.5 [32 - 81] | 42.5 [31 - 59] | 0.42 |
| Presence of proteinuria, N (%) |
0 | 9 (19.9) | 0.34 |
| Treatment | |||
| Corticosteroids, N (%) |
8 (80.0) | 27 (56.3) | 0.29 |
| Mycophenolic acid, N (%) |
10 (100) | 43 (89.6) | 0.58 |
| TMP-SMX, N (%) | 10 (100) | 37 (77.1) | 0.18 |
| PPI use, N (%) | 4 (40.0) | 23 (47.9) | 0.74 |
| Nephropathy, N (%) | |||
| Glomerular | 1 (10) | 16 (33.3) | 0.06 |
| Tubulo-interstitial | 0 | 6 (12.5) | |
| Vascular | 0 | 3 (6.3) | |
| Diabetes | 2(20) | 4 (8.3) | |
| Polycystic kidney disease |
0 | 7 (14.6) | |
| Others (including unknown) |
7 (70) | 12(25) | |
| Blood pressure | |||
| Hypertension, N (%) | 0 | 48 (100) | |
| SBP, mmHg | 125.5 [124-127] | 140 [129-146] | 0.005 |
| DBP, mmHg | 75.5 [72-81] | 83 [75.5-91.5] | 0.08 |
| Antihypertensive therapies | |||
| Number of antihypertensive agents |
0 | 1 (1-2) | <0.0001 |
| Calcium channel blocker, N (%) |
0 | 27 (56.3) | 0.001 |
| Beta-blocker, N (%) | 0 | 14 (29.2) | 0.1 |
| ACE inhibitors or ARB, N (%) |
0 | 18 (37.5) | 0.02 |
| Diuretic except thiazides, N (%) |
0 | 8 (16.7) | 0.33 |
| Others, N (%) | 0 | 11 (22.9) | 0.18 |
| Acid base | |||
| Acidosis, N (%) | 9 (90) | 34 (70.8) | 0.43 |
| Blood [HCO3-], mM | 19.5 [18 - 20] | 21.5 [20-24] | 0.01 |
| Blood [HCO3-] < 22 mmol/L, N (%) |
9 (90) | 24 (50) | 0.03 |
| Alkaline supplementation, N (%) | 6 (60) | 23 (47.9) | 0.49 |
| Potassium | |||
| Hyperkalemia, N (%) | 3 (30) | 19 (40.4) | 0.73 |
| [K+], mM | 4.18 [3.7-4.5] | 4.18 [3.9-4.8] | 0.29 |
| [K+] >4.5 mmol/L, N (%) | 3 (30) | 19 (40.4) | 0.73 |
| potassium chelating agent use, N (%) | 0 | 2 (4.2) | 1 |
Quantitative data are presented as median [IQR]. Qualitative data were expressed as frequency (N) and percentages (%). All quantitative variables were tested using the Mann-Whitney test. For qualitative variables, the Chi-square test was used. TMP-SMX, trimethoprim/sulfamethoxazole; PPI, proton pump inhibitor; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate.